[{"address1": "One World Trade Center", "address2": "22nd Floor", "city": "New York", "state": "NY", "zip": "10007", "country": "United States", "phone": "212 332 3241", "fax": "212 320 0245", "website": "https://www.axsome.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea. It is also developing AXS-05, which is in Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-07, an investigational medicine that has completed Phase III trials for the acute treatment of migraine; AXS-12, an investigational medicine, which is in Phase III trial to treat narcolepsy; AXS-14, a selective and potent norepinephrine reuptake inhibitor that has completed Phase III trial for the treatment of fibromyalgia and other conditions; and solriamfetol, a dual-acting dopamine and norepinephrine reuptake inhibitor, which has completed a Phase 2 trial for treating attention-deficit/hyperactivity disorder, and is in phase 2 major depressive, binge eating, and shift work disorder. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.", "fullTimeEmployees": 607, "companyOfficers": [{"maxAge": 1, "name": "Dr. Herriot  Tabuteau M.D.", "age": 55, "title": "Founder, Chairman, CEO & President", "yearBorn": 1968, "fiscalYear": 2023, "totalPay": 1395461, "exercisedValue": 0, "unexercisedValue": 99836880}, {"maxAge": 1, "name": "Mr. Nick  Pizzie CPA, M.B.A.", "age": 48, "title": "Chief Financial Officer", "yearBorn": 1975, "fiscalYear": 2023, "totalPay": 765483, "exercisedValue": 0, "unexercisedValue": 21085196}, {"maxAge": 1, "name": "Mr. Mark L. Jacobson M.A.", "age": 40, "title": "Chief Operating Officer", "yearBorn": 1983, "fiscalYear": 2023, "totalPay": 835837, "exercisedValue": 0, "unexercisedValue": 32287852}, {"maxAge": 1, "name": "Mr. Hunter  Murdock Esq.", "age": 43, "title": "General Counsel & Secretary", "yearBorn": 1980, "fiscalYear": 2023, "totalPay": 757312, "exercisedValue": 0, "unexercisedValue": 2159036}, {"maxAge": 1, "name": "Mr. Ari  Maizel", "title": "Chief Commercial Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 7, "boardRisk": 8, "compensationRisk": 8, "shareHolderRightsRisk": 8, "overallRisk": 8, "governanceEpochDate": 1730419200, "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 2, "previousClose": 97.83, "open": 98.35, "dayLow": 96.795, "dayHigh": 99.666, "regularMarketPreviousClose": 97.83, "regularMarketOpen": 98.35, "regularMarketDayLow": 96.795, "regularMarketDayHigh": 99.666, "beta": 1.252, "forwardPE": -103.50079, "volume": 391796, "regularMarketVolume": 391796, "averageVolume": 448090, "averageVolume10days": 641320, "averageDailyVolume10Day": 641320, "bid": 97.52, "ask": 97.99, "bidSize": 100, "askSize": 100, "marketCap": 4742530560, "fiftyTwoWeekLow": 56.66, "fiftyTwoWeekHigh": 105.0, "priceToSalesTrailing12Months": 14.01221, "fiftyDayAverage": 90.5906, "twoHundredDayAverage": 82.54455, "currency": "USD", "enterpriseValue": 4606033408, "profitMargins": -0.91874003, "floatShares": 36118040, "sharesOutstanding": 48000200, "sharesShort": 7577624, "sharesShortPriorMonth": 7758630, "sharesShortPreviousMonthDate": 1727654400, "dateShortInterest": 1730332800, "sharesPercentSharesOut": 0.1579, "heldPercentInsiders": 0.16610001, "heldPercentInstitutions": 0.86489, "shortRatio": 18.44, "shortPercentOfFloat": 0.1894, "impliedSharesOutstanding": 48462400, "bookValue": 1.918, "priceToBook": 51.0219, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1727654400, "netIncomeToCommon": -310955008, "trailingEps": -6.58, "forwardEps": -2.16, "enterpriseToRevenue": 13.609, "enterpriseToEbitda": -18.829, "52WeekChange": 0.63841903, "SandP52WeekChange": 0.3276534, "exchange": "NGM", "quoteType": "EQUITY", "symbol": "AXSM", "underlyingSymbol": "AXSM", "shortName": "Axsome Therapeutics, Inc.", "longName": "Axsome Therapeutics, Inc.", "firstTradeDateEpochUtc": 1447943400, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EST", "uuid": "dc312fd5-deeb-376b-9b93-11451c06c191", "messageBoardId": "finmb_241907563", "gmtOffSetMilliseconds": -18000000, "currentPrice": 97.86, "targetHighPrice": 180.0, "targetLowPrice": 105.0, "targetMeanPrice": 129.17647, "targetMedianPrice": 125.0, "recommendationMean": 1.29412, "recommendationKey": "strong_buy", "numberOfAnalystOpinions": 17, "totalCash": 327340992, "totalCashPerShare": 6.755, "ebitda": -244623008, "totalDebt": 192300000, "quickRatio": 2.301, "currentRatio": 2.442, "totalRevenue": 338456992, "debtToEquity": 207.001, "revenuePerShare": 7.108, "returnOnAssets": -0.26442, "returnOnEquity": -1.71606, "freeCashflow": -42439752, "operatingCashflow": -132570000, "revenueGrowth": 0.813, "grossMargins": 0.91086996, "ebitdaMargins": -0.72276, "operatingMargins": -0.44131002, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-11-14"}]